Photo of Biree  Andemariam, M.D.

Biree Andemariam, M.D.

Professor of Medicine
NPI Number:
1396935136
Academic Office Location:
Medicine
UConn Health
263 Farmington Avenue
Farmington, CT 06030-1628
Phone: 860-679-2100
  • Looking for a Physician?

    This faculty member is also
    a practicing physician at UConn Health.

    Learn more >
Education
DegreeInstitutionMajor
A.B.Princeton UniversityMolecular Biology
M.D.Tufts University School of Medicine Medicine with Honors in Research

Post-Graduate Training
TrainingInstitutionSpecialty
InternshipNew York Presbyterian Hospital/Weill Cornell Medical CollegeInternal Medicine
ResidencyNew York Presbyterian Hospital/Weill Cornell Medical CollegeInternal Medicine
FellowshipNew York Presbyterian Hospital/Weill Cornell Medical CollegeHematology/Oncology

Awards
Name of Award/HonorAwarding Organization
Cage S. Johnson, MD Sickle Cell Physician AwardCayenne Wellness Center, San Diego, CA
Connecticut Women’s Hall of Fame HonoreeConnecticut Women's Hall of Fame
Women of Innovation Award for Research Innovation and Leadership FinalistConnecticut Technology Council
Champion AwardSickle Cell Disease Association of American, Northern CT Chapter
K12 Award Connecticut Institute for Clinical and Translational Science
Hartford WKND Annual Black History Month Recognition Award Hartford WKND
Amgen Research Fellowship AwardAmgen
Clinical Research Feasibility Fund AwardGCRC/NewYork-Presbyterian Hospital/Weill Cornell
Ruth L. Kirschstein National Research Service AwardNewYork-Presbyterian Hospital/Weill Cornell Medical College/NIH
Charles Uribe Award (given to the resident with outstanding dedicated service to the minority community)NewYork-Presbyterian Hospital/Weill Cornell Medical College
Half Tuition ScholarshipTufts University School of Medicine
Ruth Easterling Award (awarded to the Tufts Medical graduate with a demonstrable commitment toward promotion of minority health)Tufts University School of Medicine
Student Forum First Place Award National Medical Association Research
Medical Student Research AwardSociety for Pediatric Research
Travel AwardAmerican Physiological Society
NIH Research Scholars Program FellowshipHoward Hughes Medical Institute
National Medical Fellowship Program in Academic Medicine Research FellowshipNational Medical Fellowship Program
Minority Summer Research Program FellowshipSociety for Pediatric Research

In 2009, we opened the region's only adult sickle cell disease clinical center in order to deliver comprehensive, state-of-the-art care. We provide consultative and comprehensive care for all hereditary hemoglobin disorders, namely sickle cell disease and thalassemia. We have a dedicated team that includes a hematologist, two nurse practitioners, a clinical nurse coordinator, infusion room nurse, social worker, and patient navigator. Our program offerings include preventative care, acute and chronic pain management, transfusions (including apheresis and exchange transfusions), the management of transfusion-related complications (e.g., iron overload and red blood cell alloantibodies), fast and efficient management of pain crises, and referrals to specialists for related conditions such as pulmonary hypertension, kidney disease, liver disease, cardiomyopathy, retinopathy, avascular necrosis, leg ulcers, priapism, pregnancy, and stroke. We serve over 200 adults lving with sickle cell disease.

Name & DescriptionCategoryRoleTypeScopeStart YearEnd Year
Sickle Cell Disease of Association of AmericaOtherVice Chair, Board of DirectorsExternalNational2011
Wilson Gray YMCA (Hartford, CT)Community ServiceDirectorExternalLocal20112012
Community Health Services, Inc.Community ServiceDirectorExternalLocal20102012
Village for Children and Families, Board of Advocates MemberExternalLocal2008
Connecticut Sickle Cell Disease StakeholdersProfessional/Scientific OrganizationMemberExternalState2007
E. E. Just Society(lifetime member)Professional/Scientific OrganizationLifetime MemberExternalNational2007
American Society of Hematology Professional/Scientific OrganizationMemberExternalNational2005
American Society of Clinical OncologyProfessional/Scientific OrganizationMemberExternalNational2004
Student National Medical AssociationProfessional/Scientific OrganizationMemberExternalNational19962002

At the New England Sickle Cell Institute, we conduct basic, translational and clinical research in sickle cell disease. Our overarching goal is to develop new insights into the fundamental causes of multi-organ morbidity and early mortality from this most common hereditary red blood cell disorder. We are specifically interested in how this hemoglobin-based disease leads to increased susceptibility to life-threatening infection and asthma. Our lab uses a mouse model of human sickle cell disease to answer these important questions. Additionally, we enroll interested humans with sickle cell disease into translational reserach studies. We collaborate locally, nationally and internationally. Our collaborating institutions include University of Connecticut (Storrs, CT), Connecticut Children's Medical Center (Hartford, CT), Hospital for Special Care (New Britain, CT), Yale University School of Medicine (New Haven, CT), University of Michigan (Ann Arbor, MI), Vanderbilt University Medical Center (Nashville, TN), University of Florida (Gainesville, FL), Case Medical Center (Cleveland, OH), Albert Einstein/Montefiore (Bronx, NY), Guys St. Thomas Hospital (London, England), University of Padova (Padova, Italy). We also have community partnerships for both clinical care and research with our two area sickle cell disease community-based organizations: Citizens for Quality Sickle Cell Care, Inc. and Sickle Cell Disease Association of America-Southern Connecticut Chapter.

Journal Articles

Book Chapters

Reviews

Title or AbstractTypeSponsor/EventDate/YearLocation
Real-Life Experience Of Novel Therapies Use: Voxelotor RETRO/PROSPECT StudiesTalkAnnual Academy for Sickle Cell and Thalassemia Conference2022Virtual
IMR-261, a Novel Oral Nrf2 Activator, Induces Fetal Hemoglobin in Human Erythroblasts, Reduces VOCs, and Ameliorates Ineffective Erythropoiesis in Experimental Mouse Models of Sickle Cell Disease and Beta-ThalassemiaTalkAmerican Society of Hematology2021Atlanta, GA
The burden of sickle cell disease (SCD) on patients in Ghana and Nigeria compared with other low-/middle-income and high-income countries: results from the sickle cell world assessment survey (SWAY)LectureSickle Cell Disease Association of America2021Virtual
The burden of sickle cell disease (SCD) on patients in Ghana and Nigeria compared with other low-/middle-income and high-income countries: results from the Sickle Cell World Assessment Survey (SWAY)Panel DiscussionEuropean Hematology Association 26th Congress2021Virtual
Clinical Advancements in Sickle Cell Disease: Current Therapeutic Approaches to Patient CareLectureAmerican Society of Hematology Satellite Symposium2021Atlanta, GA
Sickle Cell Disease: Improving the Quality and Continuum of Acute and Ambulatory Patient Care: New Approaches to Disease Modification on the HorizonLecturePhysicians Education Resource2021Virtual
Physical and Financial Access to COVID-19 VaccinationPanel DiscussionFoundation for Sickle Cell Disease Research Conference2021Virtual
Ensuring Equitable Access to New Gene TherapiesTalkMassBio:Make Shift Happen2021Virtual
Disease Modification in Sickle Cell Disease: Available and Emerging ApproachesLectureUniversity of Connecticut Health Center2021Farmington, CT
Understanding your patient population and patterns of utilizationLectureAmerican Society of Hematology Sickle Cell Disease Centers Workshop2021Virtual
Sickle Cell Disease in the 21st Century: Healing Old Wounds with New HopePlenary LectureHealth Career Opportunity Program - Black History Month2021Farmington, CT
Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension StudyPosterAmerican Society of Hematology2021Atlanta, GA
Impact of Sickle Cell Disease Symptoms on Patients’ Daily Lives in the US – Patients from the Sickle Cell World Assessment SurveyLecture2020Orlando, Florida
Menstruation Associated Pain Crises in an International Cohort of Sickle Cell WomenTalkFoundation for Sickle Cell Research Annual Meeting2020Fort Lauderdale, Florida
Pain Burden in the CASIRE Sickle Cell Cohort: United States and GhanaTalkFoundation for Sickle Cell Research Annual Meeting2020Fort Lauderdale, Florida
Impact of Sickle Cell Disease on Patients’ Daily Lives in the US: Results From the Sickle Cell World Assessment SurveyTalkFoundation for Sickle Cell Research Annual Meeting2020Fort Lauderdale, Florida
Management Strategies and Satisfaction Levels in Patients with Sickle Cell Disease in the US: Results From the Sickle Cell World Assessment SurveyTalkFoundation for Sickle Cell Research Annual Meeting2020Fort Lauderdale, Florida
IMR-687, A HIGHLY SELECTIVE PHOSPHODIESTERASE 9 INHIBITOR (PDE9I), INCREASES F-CELLS AND FETAL HEMOGLOBIN IN A PH-2A INTERIM ANALYSISTalkEuropean Hematology Association 25th Congress2020Virtual